Gastric adenocarcinoma surgery and adjuvant therapy

Surg Clin North Am. 2011 Oct;91(5):1039-77. doi: 10.1016/j.suc.2011.06.009.

Abstract

Gastric adenocarcinoma is one of the most common causes of death worldwide. Surgical resection remains the mainstay of therapy, offering the only chance for complete cure. Resection is based on the principles of obtaining adequate margins, with the extent of lymphadenectomy remaining controversial. Neoadjuvant and adjuvant therapies are used to reduce local recurrence and improve long-term survival. This article reviews the literature and provides a summary of surgical management options and neoadjuvant/adjuvant therapies for gastric adenocarcinoma.

Publication types

  • Review

MeSH terms

  • Adenocarcinoma / epidemiology
  • Adenocarcinoma / pathology
  • Adenocarcinoma / therapy*
  • Antineoplastic Agents / therapeutic use*
  • Chemotherapy, Adjuvant
  • Gastrectomy / methods*
  • Humans
  • Incidence
  • Stomach Neoplasms / epidemiology
  • Stomach Neoplasms / pathology
  • Stomach Neoplasms / therapy*
  • Survival Rate / trends
  • United States / epidemiology

Substances

  • Antineoplastic Agents